Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate…